BR112019023918A2 - Inibidores de quinase e usos dos mesmos - Google Patents
Inibidores de quinase e usos dos mesmos Download PDFInfo
- Publication number
- BR112019023918A2 BR112019023918A2 BR112019023918-9A BR112019023918A BR112019023918A2 BR 112019023918 A2 BR112019023918 A2 BR 112019023918A2 BR 112019023918 A BR112019023918 A BR 112019023918A BR 112019023918 A2 BR112019023918 A2 BR 112019023918A2
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- membered heterocyclyl
- optionally substituted
- Prior art date
Links
- 0 CCCC(NC(C)CCCC=C(C(*(C)=C)=O)C(N)=C1C(C)C1)=*S Chemical compound CCCC(NC(C)CCCC=C(C(*(C)=C)=O)C(N)=C1C(C)C1)=*S 0.000 description 6
- IRHZQIJIMBFMKC-UHFFFAOYSA-N CCOC(C1(CCNCC1)F)=O Chemical compound CCOC(C1(CCNCC1)F)=O IRHZQIJIMBFMKC-UHFFFAOYSA-N 0.000 description 2
- NINOYPKIBSQABJ-UHFFFAOYSA-N C=CNCNCCOCCC#N Chemical compound C=CNCNCCOCCC#N NINOYPKIBSQABJ-UHFFFAOYSA-N 0.000 description 1
- BXOFAAZHCXARRF-UHFFFAOYSA-N CC(C)(C)OC(C(C)(CN)C(OC)=O)=O Chemical compound CC(C)(C)OC(C(C)(CN)C(OC)=O)=O BXOFAAZHCXARRF-UHFFFAOYSA-N 0.000 description 1
- RMTDJEYZSNNPNM-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CC(C2)C12C(O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CC(C2)C12C(O)=O)=O RMTDJEYZSNNPNM-UHFFFAOYSA-N 0.000 description 1
- YGHMLBSYEVONMD-UHFFFAOYSA-N CC1(CCNCC1)C(N1Cc(cccc2)c2OCC1)=O Chemical compound CC1(CCNCC1)C(N1Cc(cccc2)c2OCC1)=O YGHMLBSYEVONMD-UHFFFAOYSA-N 0.000 description 1
- IJCZZUOFEHIIQF-UHFFFAOYSA-N CCC(C)(CC#N)C(O)=O Chemical compound CCC(C)(CC#N)C(O)=O IJCZZUOFEHIIQF-UHFFFAOYSA-N 0.000 description 1
- BGMAPPIQRFCNJE-UHFFFAOYSA-N CCC1(CCNCC1)C(N1Cc(cncc2C#N)c2OCC1)=O Chemical compound CCC1(CCNCC1)C(N1Cc(cncc2C#N)c2OCC1)=O BGMAPPIQRFCNJE-UHFFFAOYSA-N 0.000 description 1
- XCVKJAFRLKVFLH-UHFFFAOYSA-N CCOC(C(CC1)(CCN1C(c1cccnc1)=O)F)=O Chemical compound CCOC(C(CC1)(CCN1C(c1cccnc1)=O)F)=O XCVKJAFRLKVFLH-UHFFFAOYSA-N 0.000 description 1
- DQFKTBFBUUFSMW-SZSXPDSJSA-N COC(C(C1)(CC2)[C@H]1CN2c(nc1)ncc1F)=O Chemical compound COC(C(C1)(CC2)[C@H]1CN2c(nc1)ncc1F)=O DQFKTBFBUUFSMW-SZSXPDSJSA-N 0.000 description 1
- RBIGNIGHKNAOTI-UHFFFAOYSA-N COc(c(F)c1)nc(N(CC2)CCC2C(N2Cc(cncc3C#N)c3OCC2)=O)c1F Chemical compound COc(c(F)c1)nc(N(CC2)CCC2C(N2Cc(cncc3C#N)c3OCC2)=O)c1F RBIGNIGHKNAOTI-UHFFFAOYSA-N 0.000 description 1
- BUSIPILBZXDZDV-UHFFFAOYSA-N Cc1cncc(C2)c1OCCN2C(C1(CCNCC1)OC)=O Chemical compound Cc1cncc(C2)c1OCCN2C(C1(CCNCC1)OC)=O BUSIPILBZXDZDV-UHFFFAOYSA-N 0.000 description 1
- XXDCFEKEDQAQAK-UHFFFAOYSA-N Cc1cncc(C2)c1OCCN2C(C1CCNCC1)=O Chemical compound Cc1cncc(C2)c1OCCN2C(C1CCNCC1)=O XXDCFEKEDQAQAK-UHFFFAOYSA-N 0.000 description 1
- WKFACUQHIAIREB-UHFFFAOYSA-N Clc(cn[n]12)c1nccc2Cl Chemical compound Clc(cn[n]12)c1nccc2Cl WKFACUQHIAIREB-UHFFFAOYSA-N 0.000 description 1
- YCZQHXPIKQHABJ-UHFFFAOYSA-N Clc1ccnc2ccn[n]12 Chemical compound Clc1ccnc2ccn[n]12 YCZQHXPIKQHABJ-UHFFFAOYSA-N 0.000 description 1
- AGYUQBNABXVWMS-UHFFFAOYSA-N Fc(cn1)cnc1Cl Chemical compound Fc(cn1)cnc1Cl AGYUQBNABXVWMS-UHFFFAOYSA-N 0.000 description 1
- BYRXZHWQDLFNHX-UHFFFAOYSA-N Fc(cn[n]12)c1nccc2Cl Chemical compound Fc(cn[n]12)c1nccc2Cl BYRXZHWQDLFNHX-UHFFFAOYSA-N 0.000 description 1
- HHBJTDKOPREFFN-HOTGVXAUSA-N N#Cc(cncc1C2)c1OCCN2C([C@@H](CCN(C1)c(nc2)ncc2F)[C@H]1F)=O Chemical compound N#Cc(cncc1C2)c1OCCN2C([C@@H](CCN(C1)c(nc2)ncc2F)[C@H]1F)=O HHBJTDKOPREFFN-HOTGVXAUSA-N 0.000 description 1
- OLMQVPNSTNUFTA-UHFFFAOYSA-N N#Cc1cncc(C2)c1OCCN2C(C(CC1)CCN1c(nc(c(F)c1)F)c1F)=O Chemical compound N#Cc1cncc(C2)c1OCCN2C(C(CC1)CCN1c(nc(c(F)c1)F)c1F)=O OLMQVPNSTNUFTA-UHFFFAOYSA-N 0.000 description 1
- YPVZFODQGBWQHR-UHFFFAOYSA-N N#Cc1cncc(C2)c1OCCN2C(C1(CCNCC1)F)=O Chemical compound N#Cc1cncc(C2)c1OCCN2C(C1(CCNCC1)F)=O YPVZFODQGBWQHR-UHFFFAOYSA-N 0.000 description 1
- ZGQKRNZKNXYWKJ-DKSCNQEISA-N OC(C(C1)(CC2)[C@H]1CN2c(nc1)ncc1F)=O Chemical compound OC(C(C1)(CC2)[C@H]1CN2c(nc1)ncc1F)=O ZGQKRNZKNXYWKJ-DKSCNQEISA-N 0.000 description 1
- YWRBSYKJYOGRSO-UHFFFAOYSA-N OC(C(CC1)(CCN1C(c1cnccc1)=O)F)=O Chemical compound OC(C(CC1)(CCN1C(c1cnccc1)=O)F)=O YWRBSYKJYOGRSO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N OC(c1cnccc1)=O Chemical compound OC(c1cnccc1)=O PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/04—Seven-membered rings having the hetero atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507698P | 2017-05-17 | 2017-05-17 | |
| US62/507,698 | 2017-05-17 | ||
| US201862664895P | 2018-04-30 | 2018-04-30 | |
| US62/664,895 | 2018-04-30 | ||
| PCT/US2018/033266 WO2018213632A1 (en) | 2017-05-17 | 2018-05-17 | Kinase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023918A2 true BR112019023918A2 (pt) | 2020-06-02 |
Family
ID=64274744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023918-9A BR112019023918A2 (pt) | 2017-05-17 | 2018-05-17 | Inibidores de quinase e usos dos mesmos |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11203600B2 (enExample) |
| EP (1) | EP3624797A4 (enExample) |
| JP (2) | JP7064512B2 (enExample) |
| KR (1) | KR102638151B1 (enExample) |
| CN (3) | CN119264073A (enExample) |
| AU (1) | AU2018269743B2 (enExample) |
| BR (1) | BR112019023918A2 (enExample) |
| CA (1) | CA3063934A1 (enExample) |
| CL (1) | CL2019003263A1 (enExample) |
| CO (1) | CO2019012957A2 (enExample) |
| CR (1) | CR20190566A (enExample) |
| DO (1) | DOP2019000290A (enExample) |
| EC (1) | ECSP19089214A (enExample) |
| IL (1) | IL270648B2 (enExample) |
| MX (2) | MX2019013645A (enExample) |
| MY (1) | MY200328A (enExample) |
| PE (2) | PE20241932A1 (enExample) |
| PH (1) | PH12019550235A1 (enExample) |
| SG (1) | SG10201913927VA (enExample) |
| TW (1) | TWI794232B (enExample) |
| WO (1) | WO2018213632A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7273954B2 (ja) * | 2018-10-19 | 2023-05-15 | ディスアーム セラピューティクス， インコーポレイテッド | Ｎａｄ＋またはｎａｄ＋前駆体と組み合わせたｓａｒｍ１の阻害 |
| IL291665B2 (en) * | 2019-09-27 | 2025-07-01 | Univ Texas | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| TW202535863A (zh) * | 2020-02-13 | 2025-09-16 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2021187605A1 (ja) * | 2020-03-19 | 2021-09-23 | 田辺三菱製薬株式会社 | 含窒素複素環αシアノカルボニル化合物 |
| TW202214617A (zh) | 2020-06-02 | 2022-04-16 | 法商賽諾菲公司 | 作為ｒｉｐｋ１抑制劑之異㗁唑啶及其用途 |
| KR200493347Y1 (ko) | 2020-07-06 | 2021-03-17 | 박혜진 | 휴대가 용이한 마스크 |
| US20240327412A1 (en) * | 2021-02-19 | 2024-10-03 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
| US20240208986A1 (en) * | 2021-04-27 | 2024-06-27 | Merck Sharp & Dohme Llc | Phenyl azepines as ripk1 inhibitors and methods of use thereof |
| EP4329766A4 (en) * | 2021-04-27 | 2025-06-11 | Merck Sharp & Dohme LLC | RIPK1 INHIBITORS AND METHODS OF USE |
| WO2023083847A1 (en) | 2021-11-11 | 2023-05-19 | Sanofi | Isoxazolidines as ripk1 inhibitors and use thereof |
| TW202417453A (zh) * | 2022-07-25 | 2024-05-01 | 美商戴納立製藥公司 | ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶並［３，４－ｆ］［１，４］氧氮呯－９－甲腈的固體形式 |
| WO2024044151A1 (en) * | 2022-08-23 | 2024-02-29 | Genzyme Corporation | Methods for treating receptor-interacting protein kinase 1-mediated diseases |
| TW202444357A (zh) * | 2023-01-23 | 2024-11-16 | 美商健臻公司 | ４－（３，３－二氟－２，２－二甲基－丙醯基）－３，５－二氫－２ｈ－吡啶并［３，４－ｆ］［１，４］氧氮呯－９－甲腈之藥品調配物 |
| TW202515552A (zh) * | 2023-06-27 | 2025-04-16 | 美商健臻公司 | 製備4-(3,3-二氟-2,2-二甲基-丙醯基)-3,5-二氫-2h-吡啶并[3,4-f][1,4]氧雜氮呯-9-腈之方法 |
| CN120365288A (zh) * | 2024-01-23 | 2025-07-25 | 南京天印健华医药科技有限公司 | 作为ripk1抑制剂的杂环化合物 |
| CN120365287A (zh) * | 2024-01-23 | 2025-07-25 | 南京天印健华医药科技有限公司 | 作为ripk1抑制剂的杂环化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3861187B2 (ja) * | 1996-08-02 | 2006-12-20 | 住友精化株式会社 | チアゼピン誘導体の製造方法 |
| MXPA03002649A (es) | 2000-09-27 | 2003-09-25 | Ajinomoto Kk | Derivado de benzodiazepina. |
| RU2456287C1 (ru) * | 2011-05-20 | 2012-07-20 | Николай Филиппович Савчук | Стимуляторы секреции инкретиновых гормонов, способы их получения и применения |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| CN104059068B (zh) | 2013-03-20 | 2017-02-08 | 中国科学院上海药物研究所 | β‑氨基羰基类化合物、其制备方法、药物组合物及其用途 |
| CN107801396B (zh) * | 2015-02-02 | 2021-10-22 | 福马治疗股份有限公司 | 作为hdac抑制剂的3-芳基-4-酰氨基-二环[4,5,0]异羟肟酸 |
| UY36680A (es) * | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| PH12017502255B1 (en) * | 2015-06-15 | 2022-07-22 | Astex Therapeutics Ltd | Nrf2 regulators |
-
2018
- 2018-05-17 JP JP2019563596A patent/JP7064512B2/ja active Active
- 2018-05-17 SG SG10201913927VA patent/SG10201913927VA/en unknown
- 2018-05-17 PE PE2024000411A patent/PE20241932A1/es unknown
- 2018-05-17 CA CA3063934A patent/CA3063934A1/en active Pending
- 2018-05-17 CN CN202411240964.3A patent/CN119264073A/zh active Pending
- 2018-05-17 TW TW107116834A patent/TWI794232B/zh active
- 2018-05-17 CN CN201880047293.5A patent/CN110913858B/zh active Active
- 2018-05-17 KR KR1020197036911A patent/KR102638151B1/ko active Active
- 2018-05-17 IL IL270648A patent/IL270648B2/en unknown
- 2018-05-17 AU AU2018269743A patent/AU2018269743B2/en active Active
- 2018-05-17 PE PE2019002424A patent/PE20200729A1/es unknown
- 2018-05-17 CR CR20190566A patent/CR20190566A/es unknown
- 2018-05-17 BR BR112019023918-9A patent/BR112019023918A2/pt not_active Application Discontinuation
- 2018-05-17 MX MX2019013645A patent/MX2019013645A/es unknown
- 2018-05-17 CN CN202411240962.4A patent/CN119285572A/zh active Pending
- 2018-05-17 WO PCT/US2018/033266 patent/WO2018213632A1/en not_active Ceased
- 2018-05-17 EP EP18802127.3A patent/EP3624797A4/en active Pending
- 2018-05-17 MY MYPI2019006664A patent/MY200328A/en unknown
-
2019
- 2019-11-13 PH PH12019550235A patent/PH12019550235A1/en unknown
- 2019-11-14 CL CL2019003263A patent/CL2019003263A1/es unknown
- 2019-11-14 DO DO2019000290A patent/DOP2019000290A/es unknown
- 2019-11-14 US US16/684,340 patent/US11203600B2/en active Active
- 2019-11-14 MX MX2022010755A patent/MX2022010755A/es unknown
- 2019-11-19 CO CONC2019/0012957A patent/CO2019012957A2/es unknown
- 2019-12-16 EC ECSENADI201989214A patent/ECSP19089214A/es unknown
-
2021
- 2021-09-09 JP JP2021146775A patent/JP7241825B2/ja active Active
- 2021-10-26 US US17/511,193 patent/US12129263B2/en active Active
-
2024
- 2024-09-18 US US18/889,058 patent/US20250011338A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019023918A2 (pt) | Inibidores de quinase e usos dos mesmos | |
| JP7518049B2 (ja) | Ｐａｒｐ７阻害剤としてのピリダジノン | |
| CN112778276B (zh) | 作为shp2抑制剂的化合物及其应用 | |
| TWI378101B (en) | Pyridine derivatives and their use in the treatment of psychotic disorders | |
| EP2943485B1 (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | |
| KR102517352B1 (ko) | Nik 억제제로서의 헤테로방향족 유도체 | |
| KR20160144378A (ko) | 브루톤 티로신 키나제 억제제로서 작용하는 폴리플루오로화 화합물 | |
| CA2953798A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| TW201414737A (zh) | 作爲激酶抑制劑之咪唑并三□甲腈 | |
| CN102372698A (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| ES2869129T3 (es) | Agonistas de piperidinona del receptor 2 de péptidos formilados | |
| CN106061980A (zh) | 作为mknk1和mknk2抑制剂的噻吩并嘧啶 | |
| EP3625234B1 (en) | Hexahydropyrazolo [1,2-a] diazepinones and related heterocycles as inhibitors of rip-1 kinase | |
| KR20230083276A (ko) | 오토탁신 억제제 화합물 | |
| ES2896938T3 (es) | Inhibidores de GSK-3 | |
| JP2025530793A (ja) | Ｅｇｆｒ阻害剤及びその使用 | |
| EP4305040A1 (en) | Tricyclic pyridines as cyclin-dependent kinase 7 (cdk7) inhibitors | |
| HK1216316B (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |